Abstract: A method for treating narcolepsy type 1 in a subject in need thereof is disclosed, comprising administering to the subject an effective amount of methyl 3-((methylsulfonyl)anhino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate (Compound (I)), or a salt thereof, wherein plasma concentration for Compound (I) is about 5.04 ng/mL or more for about 1 hour or more. Compositions for treating narcolepsy type 1 comprising Compound (I) are also disclosed.

Abstract: Described herein are methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)-piperidine-1-carboxylate (Compound (I)), compositions comprising Compound (I), and the use of Compound (I) for the treatment of excessive sleepiness in a subject in need thereof.

Abstract: Assays for detecting or measuring inositol phosphate, for detecting or measuring signaling pathways, for detecting or measuring the activity of phospholipase C-linked receptors and/or their cognate pathways, for detecting or measuring the activity of inositol kinases and inositol phosphatases, and for screening for compounds that modulate the activity of signaling pathways, receptors and enzymes.

Abstract: A method of treating or preventing illnesses caused by a disorder of the dopamine system. The method comprises administering to a host requiring such treatment or prevention an effective amount of a pharmaceutical composition comprising a compound of the formula ##STR1## wherein R.sup.1 is hydrogen, lower-alkyl, halogen, lower-alkoxy or nitro;R.sub.2 is hydrogen, lower alkyl or trifluoromethyl; andR.sup.3 is hydrogen, lower alkyl, trifluoromethyl, benzyl, hydroxy-lower-alkyl, lower alkoxy, lower-alkyl-carbonyl-amino, carbonyl-lower-alkyl, benzyl, di-lower-alkyl-amino-carbonyl, carbonylamino or amino-carbonyl-amino; orR.sup.2 and R.sup.3 together optionally are a fused benzene ring andR.sup.4 is hydrogen or halogen,or a pharmaceutically acceptable salt of a compound of formula I, and a pharmaceutically inert carrier material.

Abstract: A method of treating or preventing illnesses caused by a disorder of the dopamine system. The method comprises administering to a host in need of such treatment or prevention an effective amount of a pharmaceutical composition comprising a compound of the formula ##STR1## wherein R.sup.1 and R.sup.3 each independently are hydrogen, aryl, carbamoyl, lower-alkyl-carbonyl, lower-alkyl, halogen, lower-alkyl-carbonyl-amino, lower-alkenyl-carbonyl-amino, amino, arylamino, aryloxy, nitro, aryl-acetyl, lower-alkanoyl-lower-alkyl, alkyl-sulphonyl-amino, ureido or furan-2-yl-carbonyl-amino andR.sup.2 is hydrogen, lower-alkyl, trifluoromethyl, halogen, lower-alkoxy, lower-alkyl-carbonyl or lower-alkyl-carbonyl-amino orR.sup.1 and R.sup.2 together are --OCH.sub.2 O--, --O(CH.sub.2).sub.2 O-- or --(CH.sub.2).sub.3 --,R.sup.4 is hydrogen, halogen, hydroxy, lower-alkyl, lower-alkoxy or nitro,R.sup.5 is hydrogen, halogen or lower-alkoxy,R.sup.